OTCMKTS:OPHLY Ono Pharmaceutical (OPHLY) Stock Price, News & Analysis $5.02 +0.09 (+1.83%) As of 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About Ono Pharmaceutical Stock (OTCMKTS:OPHLY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ono Pharmaceutical alerts:Sign Up Key Stats Today's Range$4.98▼$5.0750-Day Range$4.65▼$5.4052-Week Range$3.82▼$5.75Volume20,912 shsAverage Volume36,484 shsMarket CapitalizationN/AP/E Ratio1.10Dividend Yield330.15%Price TargetN/AConsensus RatingN/A Company Overview Ono Pharmaceutical Co., Ltd. is a Japan-based, research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its activities focus primarily on areas of high unmet medical need, including oncology, immunology, neurology and other specialty-care fields. The company’s best-known product is Opdivo (nivolumab), an immune checkpoint inhibitor used in the treatment of multiple cancers. Ono has also developed or commercialized other specialty medicines, including treatments for cancer and immune-related conditions, through internal research and collaborations with pharmaceutical companies in Japan and overseas. Ono Pharmaceutical traces its origins to 1717, when it began as a drug wholesaler in Osaka, and was incorporated in its modern corporate form in 1947. The company is headquartered in Osaka, Japan, and serves the Japanese market while supporting international distribution and development through licensing, alliances and partnerships. Its shares are also represented in the United States through the OTC Markets under the symbol OPHLY.AI Generated. May Contain Errors. Read More Receive OPHLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OPHLY Stock News HeadlinesOno Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Stock Short Interest Falls 64.6%October 12, 2026 | americanbankingnews.comOno Pharmaceutical Secures Asian Rights to Biohaven's Autoimmune DrugsOctober 9, 2026 | marketscreener.comMDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarter he swaps in a brand-new list, and once the new edition launches, this one disappears. Investors who want a current snapshot of his picks should grab a copy now and save it before the switch happens.October 16 at 1:00 AM | Profits Run (Ad)Biohaven Ltd. Enters Strategic Licensing Agreement with Ono Pharmaceutical Co., Ltd. for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 ...October 8, 2026 | marketscreener.comMOno Pharmaceutical : Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize IgG Degraders in Japan, South Korea, Taiwan, and ASEAN CountriesOctober 8, 2026 | marketscreener.comMBiohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves ...October 8, 2026 | markets.ft.comBiohaven Licenses IgG Degrader Portfolio To Ono Pharma In Key Asian MarketsOctober 8, 2026 | rttnews.comOno Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological DiseasesSeptember 1, 2026 | businesswire.comSee More Headlines OPHLY Stock Analysis - Frequently Asked Questions How have OPHLY shares performed this year? Ono Pharmaceutical's stock was trading at $4.55 at the beginning of the year. Since then, OPHLY shares have increased by 10.2% and is now trading at $5.0150. How do I buy shares of Ono Pharmaceutical? Shares of OPHLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/16/2026Next Earnings (Estimated)10/28/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:OPHLY CIK940821 Webwww.ono-pharma.com Phone(166) 263-5670FaxN/AEmployees4,206Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio1.10 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (OTCMKTS:OPHLY) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ono Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ono Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPHLY Stock Alerts